Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02141074
Registration number
NCT02141074
Ethics application status
Date submitted
28/03/2014
Date registered
19/05/2014
Date last updated
26/03/2024
Titles & IDs
Public title
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
Query!
Scientific title
An Open-label Single-arm Multicentre Non-controlled Phase 3 a Trial Investigating Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Patients With Haemophilia B (FIX Activity Below or Equal to 2 Percent)
Query!
Secondary ID [1]
0
0
2012-004867-38
Query!
Secondary ID [2]
0
0
NN7999-3895
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
paradigm™6
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Congenital Bleeding Disorder
0
0
Query!
Haemophilia B
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Blood
0
0
0
0
Query!
Clotting disorders
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - nonacog beta pegol
Experimental: 50 EDs (exposure days) -
Treatment: Drugs: nonacog beta pegol
For intravenous (i.v.) injection. A single dose of 40 U/kg, unless the bleeding episode is severe in which case it should be treated with 80 U/kg.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) (50 Exposure Days)
Query!
Assessment method [1]
0
0
Number of participants with incidence of inihibitory antibodies against FIX after 50 ED is presented and defined as an inhibitory antibody titre greater than equal to 0.6 Bethesda unit (BU) at two consecutive tests performed at the central laboratory and also tested positive for nonacog beta pegol binding antibodies.
Query!
Timepoint [1]
0
0
When minimum 20 previously untreated patients (PUPs) have reached at least 50 exposure days (ED) (up to 156 weeks)
Query!
Primary outcome [2]
0
0
Number of Participants With Incidence of Inhibitory Antibodies Against FIX (100 ED)
Query!
Assessment method [2]
0
0
Number of participants with incidence of inihibitory antibodies against FIX after 100 ED is presented and defined as an inhibitory antibody titre greater than equal to 0.6 Bethesda unit (BU) at two consecutive tests performed at the central laboratory and also tested positive for nonacog beta pegol binding antibodies.
Query!
Timepoint [2]
0
0
When minimum 40 PUPs have reached at least 100 ED (up to 208 weeks)
Query!
Primary outcome [3]
0
0
Number of Participants With Incidence of Inhibitory Antibodies Against FIX (At End of Trial)
Query!
Assessment method [3]
0
0
Number of participants with incidence of inihibitory antibodies against FIX at end of trial is presented and defined as an inhibitory antibody titre greater than equal to 0.6 Bethesda unit (BU) at two consecutive tests performed at the central laboratory and also tested positive for nonacog beta pegol binding antibodies.
Query!
Timepoint [3]
0
0
At end of trial (up to 434 weeks)
Query!
Secondary outcome [1]
0
0
Number of Adverse Events
Query!
Assessment method [1]
0
0
Number of adverse events after 50 ED, after 100 ED, and at end of trial is presented. An adverse event was defined as any untoward medical occurrence in a participant who was administered a product, and which does not necessarily have a causal relationship with this treatment. All presented adverse events are treatment emergent adverse events, defined as an event that occured while the participant was on treatment in the period from first dosing with nonacog beta pegol to the end of trial/discontinuation of treatment.
Query!
Timepoint [1]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks); at end of trial (up to 434 weeks)
Query!
Secondary outcome [2]
0
0
Frequency of Adverse Events
Query!
Assessment method [2]
0
0
Frequency of adverse events after 50 ED, after 100 ED, and at end of trial is presented. Frequency of adverse events was expressed as number of adverse events per participant years of exposure (total number of events /total time in trial). An adverse event was defined as any untoward medical occurrence in a participant who was administered a product, and which does not necessarily have a causal relationship with this treatment. All presented adverse events are treatment emergent adverse events, defined as an event that occured while the participant was on treatment in the period from first dosing with nonacog beta pegol to the end of trial/discontinuation of treatment.
Query!
Timepoint [2]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks); at end of trial (up to 434 weeks)
Query!
Secondary outcome [3]
0
0
Number of Serious Adverse Events
Query!
Assessment method [3]
0
0
Number of serious adverse events after 50 ED, after 100 ED, and at end of trial is presented. A serious adverse event was an experience that at any dose resulted in: death; life-threatening experience; in-patient hospitalisation or prolongation of existing hospitalisation; a persistent or significant disability/incapacity; congenital anomaly/birth defect; important medical events that may not result in death, be life-threatening/require hospitalisation could be considered a serious adverse event based upon appropriate medical judgement.
Query!
Timepoint [3]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks); at end of trial (up to 434 weeks)
Query!
Secondary outcome [4]
0
0
Frequency of Serious Adverse Events
Query!
Assessment method [4]
0
0
Frequency of serious adverse events after 50 ED, after 100 ED, and at end of trial is presented. Frequency of serious adverse events was expressed as number of serious adverse events per participant years of exposure (total number of events /total time in trial). A serious adverse event was an experience that at any dose resulted in: death; life-threatening experience; in-patient hospitalisation or prolongation of existing hospitalisation; a persistent or significant disability/incapacity; congenital anomaly/birth defect; important medical events that may not result in death, be life-threatening/require hospitalisation could be considered a serious adverse event based upon appropriate medical judgement.
Query!
Timepoint [4]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks); at end of trial (up to 434 weeks)
Query!
Secondary outcome [5]
0
0
Number of Medical Events of Special Interest
Query!
Assessment method [5]
0
0
Number of medical events of special interest after 50 ED, after 100 ED, and at end of trial is presented. A medical event of special interest (MESI) was an event that, in the evaluation of safety, has a special focus. A MESI was an adverse event (serious or non-serious adverse event) that fulfils one or more of the following MESI criteria: 1. Medication errors concerning the trial product; 2. Inhibitor formation against FIX; 3. Thromboembolic events; 4. Anaphylactic reaction; 5. Allergic reaction including, but not limited to, any acute immunoglobulin E mediated reaction of delayed-type hypersensitivity (clinical signs may include various types of skin rashes) that does not meet the definition of anaphylaxis; 6. CNS-related adverse events including, but not limited to, any learning and behavioral deficits; 7. Renal adverse events including new onset of renal disorder or renal impairment or acute and chronic renal failure.
Query!
Timepoint [5]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks); at end of trial (up to 434 weeks)
Query!
Secondary outcome [6]
0
0
Frequency of Medical Events of Special Interest
Query!
Assessment method [6]
0
0
Frequency of medical events of special interest after 50 ED, after 100 ED, and at end of trial is presented. It was expressed as number of MESI per participant years of exposure (total number of events/total time in trial). A MESI was an event that, in the evaluation of safety, has a special focus. A MESI was an adverse event that fulfils one or more of the MESI criteria: 1. Medication errors concerning the trial product; 2. Inhibitor formation against FIX; 3. Thromboembolic events; 4. Anaphylactic reaction; 5. Allergic reaction including, but not limited to, any acute immunoglobulin E mediated reaction of delayed-type hypersensitivity (clinical signs may include various types of skin rashes) that does not meet the definition of anaphylaxis; 6. CNS-related adverse events including, but not limited to, any learning and behavioral deficits; 7. Renal adverse events including new onset of renal disorder or renal impairment or acute and chronic renal failure.
Query!
Timepoint [6]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks); at end of trial (up to 434 weeks)
Query!
Secondary outcome [7]
0
0
Number of Breakthrough Bleeding Episodes During Prophylaxis (Annualised Bleeding Rate)
Query!
Assessment method [7]
0
0
Number of breakthrough bleeding episodes during prophylaxis (annualised bleeding rate) after 50 ED, after 100 ED, and at end of trial is presented. Annualised bleeding rate is the number of bleeding episodes per year.
Query!
Timepoint [7]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks); at end of trial (up to 434 weeks)
Query!
Secondary outcome [8]
0
0
Haemostatic Effect of Nonacog Beta Pegol in Treatment of Bleeding Episodes by 4-point Haemostatic Response Scale ("Excellent", "Good", "Moderate" and "Poor")
Query!
Assessment method [8]
0
0
Haemostatic effect of nonacog beta pegol in treatment of bleeding episodes by 4-point haemostatic response scale after 50 ED, after 100 ED, and at end of trial is presented. The haemostatic response after treatment of a bleed with nonacog beta pegol was evaluated on a 4-point scale as excellent, good, moderate or poor. Excellent: abrupt pain relief and/or clear improvement in objective signs of bleeding; Good: noticeable pain relief and/or improvement in signs of bleeding; Moderate: probable or slight beneficial effect after the first injection; Poor: no improvement or worsening of symptoms. If the haemostatic response was rated as excellent or good, the treatment of the bleed was considered a success. If the haemostatic response was rated as moderate or poor, the treatment was considered a failure.
Query!
Timepoint [8]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks); at end of trial (up to 434 weeks)
Query!
Secondary outcome [9]
0
0
Incremental Recovery at 30 Minutes (IR30min)
Query!
Assessment method [9]
0
0
Incremental recovery 30 minutes post dosing (IR30min) after 50 ED, after 100 ED is presented. IR30min was defined as the rise in FIX activity per international units per kilogram (IU/kg) administered and was recorded 30 minutes after the end of nonacog beta pegol injection. It was calculated as the baseline adjusted FIX activity recorded 30 minutes after ended nonacog beta pegol injection divided by the administered dose (IU/kg body weight). It was recorded as international units per milliliter (IU/mL)/international units per kilogram (IU/kg).
Query!
Timepoint [9]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks)
Query!
Secondary outcome [10]
0
0
FIX Activity at 30 Minutes (C30min)
Query!
Assessment method [10]
0
0
FIX Activity 30 minutes post dosing (C30min) after 50 ED, after 100 ED is presented. The FIX activity was measured by one-stage clotting assay - a modified activated partial thromboplastin time (aPTT) assay.
Query!
Timepoint [10]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks)
Query!
Secondary outcome [11]
0
0
FIX Trough Levels
Query!
Assessment method [11]
0
0
FIX trough levels after 50 ED, after 100 ED, and at end of trial is presented. FIX trough level was defined as the activity recorded immediately before nonacog beta pegol injection was given and was measured by one-stage clotting assay - a modified activated partial thromboplastin time (aPTT) assay. The analysis is based on a mixed model on the log-transformed plasma concentrations with participant as a random effect. The mean trough level is presented back-transformed to the natural scale.
Query!
Timepoint [11]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks); at end of trial (up to 434 weeks)
Query!
Secondary outcome [12]
0
0
Amount of Drug Administered to Treat a Bleeding Episode
Query!
Assessment method [12]
0
0
Amount of nonacog beta pegol administered (average dose of nonacog beta pegol) to treat a bleeding episode after 50 ED, after 100 ED, and at end of trial is presented as international units per kilogram per bleed (IU/kg/bleed).
Query!
Timepoint [12]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks); at end of trial (up to 434 weeks)
Query!
Secondary outcome [13]
0
0
Number of Injections Needed to Treat a Bleeding Episode
Query!
Assessment method [13]
0
0
The mean number of injections needed to treat a bleeding episode is presented.
Query!
Timepoint [13]
0
0
When minimum 20 PUPs have reached at least 50 ED (up to 156 weeks); when minimum 40 PUPs have reached at least 100 ED (up to 208 weeks); at end of trial (up to 434 weeks)
Query!
Eligibility
Key inclusion criteria
* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
* Male, age below 6 years at the time of signing informed consent
* Patients with the diagnosis of haemophilia B (FIX (coagulation factor IX) activity level below or equal to 2%) based on medical records or central laboratory results
* Previously untreated or exposed to FIX containing products less than or equal to 3 exposure days (5 previous exposures to blood components is acceptable)
Query!
Minimum age
0
Years
Query!
Query!
Maximum age
6
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Any history of FIX inhibitors (defined by medical records)
* Known or suspected hypersensitivity to trial product or related products
* Previous participation in this trial. Participation is defined as first dose administered of trial product
* Receipt of any investigational medicinal product within 30 days before screening
* Congenital or acquired coagulation disorder other than haemophilia B
* Any chronic disorder or severe disease which, in the opinion of the Investigator, might jeopardise the patient's safety or compliance with the protocol
* Patient's parent(s)/LAR(s) (legally acceptable representative) mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
2/07/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/10/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
54
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Royal Children's Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
3052 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Idaho
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Louisiana
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Nebraska
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
North Carolina
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Ohio
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Pennsylvania
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Tennessee
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Utah
Query!
Country [10]
0
0
Algeria
Query!
State/province [10]
0
0
Algiers
Query!
Country [11]
0
0
Algeria
Query!
State/province [11]
0
0
Setif
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
Caba
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
Cordoba
Query!
Country [14]
0
0
Austria
Query!
State/province [14]
0
0
Graz
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Innsbruck
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
Klagenfurt
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Linz
Query!
Country [18]
0
0
Austria
Query!
State/province [18]
0
0
Salzburg
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
St. Poelten
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Wien
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Ontario
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Clermont Ferrand
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Kremlin-Bicêtre
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Nantes Cedex 1
Query!
Country [25]
0
0
Israel
Query!
State/province [25]
0
0
Tel-Hashomer
Query!
Country [26]
0
0
Japan
Query!
State/province [26]
0
0
Saitama
Query!
Country [27]
0
0
Malaysia
Query!
State/province [27]
0
0
Pahang
Query!
Country [28]
0
0
Malaysia
Query!
State/province [28]
0
0
Georgetown, Penang
Query!
Country [29]
0
0
Malaysia
Query!
State/province [29]
0
0
Klang, Selangor
Query!
Country [30]
0
0
Malaysia
Query!
State/province [30]
0
0
Kuala Lumpur
Query!
Country [31]
0
0
Spain
Query!
State/province [31]
0
0
Esplugues Llobregat
Query!
Country [32]
0
0
Spain
Query!
State/province [32]
0
0
Madrid
Query!
Country [33]
0
0
Spain
Query!
State/province [33]
0
0
Valencia
Query!
Country [34]
0
0
Taiwan
Query!
State/province [34]
0
0
Changhua
Query!
Country [35]
0
0
Taiwan
Query!
State/province [35]
0
0
Kaohsiung
Query!
Country [36]
0
0
Taiwan
Query!
State/province [36]
0
0
Taichung
Query!
Country [37]
0
0
Taiwan
Query!
State/province [37]
0
0
Taipei
Query!
Country [38]
0
0
Thailand
Query!
State/province [38]
0
0
Bangkok
Query!
Country [39]
0
0
Thailand
Query!
State/province [39]
0
0
Chiang Mai
Query!
Country [40]
0
0
United Kingdom
Query!
State/province [40]
0
0
Birmingham
Query!
Country [41]
0
0
United Kingdom
Query!
State/province [41]
0
0
Leicester
Query!
Country [42]
0
0
United Kingdom
Query!
State/province [42]
0
0
London
Query!
Country [43]
0
0
United Kingdom
Query!
State/province [43]
0
0
Oxford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novo Nordisk A/S
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02141074
Query!
Trial related presentations / publications
Chan AK, Alamelu J, Barnes C, Chuansumrit A, Garly ML, Meldgaard RM, Young G. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients. Res Pract Thromb Haemost. 2020 Jul 29;4(7):1101-1113. doi: 10.1002/rth2.12412. eCollection 2020 Oct.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Global Clinical Registry (GCR, 1452)
Query!
Address
0
0
Novo Nordisk A/S
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/74/NCT02141074/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/74/NCT02141074/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02141074
Download to PDF